of decline across cancer sites. I analyze the effect that pharmaceutical innovation had on premature cancer mortality in … Canada during the period 2000-2011, by investigating whether the cancer sites that experienced more pharmaceutical innovation … that pharmaceutical innovation during the period 1985-1996 reduced the number of years of potential life lost to cancer …

the elasticity of innovation with respect to the expected price of drugs should be at least as great as the elasticity of … innovation with respect to expected market size (disease incidence). I examine the cross-sectional relationship between … pharmaceutical innovation and market size among a set of diseases (different types of cancer) exhibiting substantial exogenous …

We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to …

I analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during … that there were no pre‐dated factors that drove both innovation and mortality and that there would have been parallel … trends in mortality in the absence of innovation, the estimates indicate that there were three major sources of the 13 …

I examine the impact of pharmaceutical innovation, as measured by the vintage (world launch year) of prescription drugs …

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

the health of Americans during the period 1990-2003. We hypothesize that, the more medical innovation there is related to … hypothesis, we estimate models of health outcomes using longitudinal disease-level data. We measure innovation in five types of … outpatient drug innovation had larger increases in mean age at death, controlling for other medical innovation rates and initial …